Percutaneous local therapies for hepatocellular carcinoma impair gastric function

作     者：Fumihiko Kinekawa Kazuya Matsuda Tsutomu Masaki Kazutaka Kurokohchi Hirohito Yoneyama Hideyuki Inoue Hirohide Kurata Yoshihito Uchida Seishiro Watanabe Shigeki Kuriyama 

作者机构：Third Department of Internal MedicineKagawa University School of Medicine1750-1 lkenobeMiki-choKita-gunKagawa 761-0793Japan Department of Internal MedicineMatsuda Clinic1-3-20 Fujitsuka-choTakamatsu-cityKagawa 760-0071Japan Department of Internal MedicineTakuma Municipal National Health Insurance Eikoh Hospital1381 TakumaTakuma-choMitoyo-gunKagawa 769-1101Japan 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2006年第12卷第1期

页      面：157-158页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Electrogastrography Gastric myentericactivity Hepatocellular carcinoma, Percutaneous ethanolinjection Radiofrequency ablation 

摘      要：Percutaneous local therapies, such as percutaneous ethanol injection （PEI）, microwave coagulation and radiofrequency ablation （RFA）, are frequently used worldwide for the treatment of hepatocellular carcinoma （HCC） because of their high effectiveness. Although these treatment modalities can induce effectively coagulated tumor necrosis in the liver, they may cause adverse effects on extrahepatic abdominal organs. There are, however, no published reports on the influence of percutaneous local therapies on the gastric myenteric activity. Therefore, it is unclear whether or not gastric function is affected by percutaneous local therapies. In this study, to make clear the effect of PEI and RFA on the gastric function, we continuously recorded the gastric myoelectric activity by electrogastrography （EGG） and estimated the effect of percutaneous local therapies for HCC on gastric function.